Could one dose beat two? new trial tests simpler treatment for parasitic liver disease
NCT ID NCT06367361
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether one or two doses of the drug oxfendazole can cure chronic fascioliasis (a liver infection caused by a parasite) as well as the standard two-dose treatment with triclabendazole. About 336 adults in Peru will be randomly assigned to one of three groups. Researchers will check for parasite eggs in stool samples 7 and 30 days after treatment to see if the infection is gone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oxfendazole
- What this could lead to
- If successful, this could provide a simpler, one-dose treatment option for fascioliasis, a parasitic liver infection.
- What could go wrong
- This is a Phase 2 trial with 336 participants, so results are preliminary. The drug may not be as effective as the standard treatment, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FASCIOLIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.